{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:44:13Z","timestamp":1791233053245,"version":"4.1.0"},"reference-count":135,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Alterations in gut microbial ecology have been linked to obesity, type 2 diabetes (T2D), and hypertension, but their biological significance remains difficult to separate from diet, medication use, adiposity, and other host factors. We synthesize evidence on intestinal barrier dysfunction, microbial translocation, low-grade inflammation, and microbiota-derived metabolites as interconnected mechanisms across these disorders. SCFAs, bile acids, trimethylamine N-oxide, tryptophan derivatives, branched-chain amino acid metabolites, and phenylacetylglutamine influence epithelial function, immune activation, insulin signaling, lipid handling, vascular tone, and renal physiology. Cross-cohort comparisons identify the greatest taxonomic overlap between obesity and T2D, whereas hypertension is characterized more consistently by shifts in community structure than by reproducible disease-specific taxa. Dietary modification, prebiotics, probiotics, synbiotics, postbiotics, and fecal microbiota transplantation produce modest and variable benefits, often shaped by baseline microbial features and clinical phenotype. The mechanistic and comparative data position the microbiome as a context-dependent contributor rather than an independent cause of cardiometabolic dysfunction. Progress requires longitudinal cohorts, repeated sampling, integrated multi-omics, standardized protocols, diverse populations, and prospective validation of functional biomarkers and treatment-response signatures before translation into clinical practice.<\/jats:p>","DOI":"10.3389\/fendo.2026.1948038","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:21:25Z","timestamp":1787664085000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The gut microbiome\u2013cardiometabolic axis: insights into obesity, type 2 diabetes, and hypertension"],"prefix":"10.3389","volume":"17","author":[{"given":"Jhommara","family":"Bautista","sequence":"first","affiliation":[{"name":"Cancer Research Group (CRG), Faculty of Medicine, Universidad de Las Am\u00e9ricas","place":["Quito, Ecuador"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Hern\u00e1ndez-Le\u00f3n","sequence":"additional","affiliation":[{"name":"Cancer Research Group (CRG), Faculty of Medicine, Universidad de Las Am\u00e9ricas","place":["Quito, Ecuador"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Valencia-Valverde","sequence":"additional","affiliation":[{"name":"Departamento Cirugia General y Bari\u00e1trica, Hospital General San Francisco IEES","place":["Quito, Ecuador"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Cancer Research Group (CRG), Faculty of Medicine, Universidad de Las Am\u00e9ricas","place":["Quito, Ecuador"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2026.1689708","article-title":"The global burden of cardiovascular diseases attributable to high body mass index, 1990-2023","volume":"13","author":"Sun","year":"2026","journal-title":"Front Cardiovasc Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2024.07.017","article-title":"The central role of the gut microbiota in the pathophysiology and management of type 2 diabetes","volume":"32","author":"Baars","year":"2024","journal-title":"Cell Host Microbe"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000247","article-title":"Hypertension and the gut microbiome: A science advisory from the american heart association","volume":"82","author":"Yang","year":"2025","journal-title":"Hypertension"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01688-4","article-title":"Microbiome and metabolome features of the cardiometabolic disease spectrum","volume":"28","author":"Fromentin","year":"2022","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-022-00771-0","article-title":"The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease","volume":"20","author":"Chakaroun","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104821","article-title":"Gut microbiota in the pathogenesis and therapeutic approaches of diabetes","volume":"97","author":"Crudele","year":"2023","journal-title":"EBioMedicine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"9358","DOI":"10.1038\/s41467-024-53832-y","article-title":"Identification of gut microbiome features associated with host metabolic health in a large population-based cohort","volume":"15","author":"Keshet","year":"2024","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41564-024-01870-z","article-title":"Gut microbiome signatures of vegan, vegetarian and omnivore diets and associated health outcomes across 21,561 individuals","volume":"10","author":"Fackelmann","year":"2025","journal-title":"Nat Microbiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122304","article-title":"Review on chronic metabolic diseases surrounding bile acids and gut microbiota: What we have explored so far","volume":"336","author":"Zhu","year":"2024","journal-title":"Life Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41522-026-00952-6","article-title":"Specific gut microbes are associated with the incidence of cardiometabolic disease in the HELIUS cohort","volume":"12","author":"Verhaar","year":"2026","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02932-23","article-title":"High-throughput DNA extraction strategy for fecal microbiome studies","volume":"12","author":"Isok\u00e4\u00e4nt\u00e4","year":"2024","journal-title":"Microbiol Spectr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"16816","DOI":"10.1038\/s41598-024-67499-4","article-title":"Optimised human stool sample collection for multi-omic microbiota analysis","volume":"14","author":"Gemmell","year":"2024","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09854-7","article-title":"Gut micro-organisms associated with health, nutrition and dietary interventions","volume":"650","author":"Asnicar","year":"2026","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40168-025-02273-w","article-title":"Deciphering the personalized functional redundancy hierarchy in the gut microbiome","volume":"14","author":"Jiang","year":"2025","journal-title":"Microbiome"},{"key":"B15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11883-023-01183-2","article-title":"Targeting the gut microbiome to treat cardiometabolic disease","volume":"26","author":"Theofilis","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/1040841X.2026.2629269","article-title":"Reprogramming human health through the microbiome and precision medicine","volume":"52","author":"Bautista","year":"2026","journal-title":"Crit Rev Microbiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/apha.14193","article-title":"The gut-immune axis during hypertension and cardiovascular diseases","volume":"240","author":"Dinakis","year":"2024","journal-title":"Acta Physiol (Oxf)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmic.2025.100139","article-title":"Short-chain fatty acids (SCFAs) in gut health: Implications for drug metabolism and therapeutics","volume":"25","author":"Sankarganesh","year":"2025","journal-title":"Med Microecol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-022-00654-0","article-title":"The gut microbiome and hypertension","volume":"19","author":"O\u2019Donnell","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S318327","article-title":"Role of goblet cells in intestinal barrier and mucosal immunity","volume":"14","author":"Yang","year":"2021","journal-title":"J Inflammation Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1827694","article-title":"Host\u2013microbiome interactions in breast cancer progression and treatment response","volume":"13","author":"Bautista","year":"2026","journal-title":"Front Med (Lausanne)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41522-025-00883-8","article-title":"Gut microbiome-driven colorectal cancer via immune, metabolic, neural, and endocrine axes reprogramming","volume":"12","author":"Bautista","year":"2026","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/microorganisms10010068","article-title":"Physiological role of bile acids modified by the gut microbiome","volume":"10","author":"Kiriyama","year":"2021","journal-title":"Microorganisms"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1689026","article-title":"Bile acid-microbiota interactions in cardiometabolic diseases: mechanisms and emerging therapeutic approaches","volume":"16","author":"Chen","year":"2025","journal-title":"Front Microbiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.cell.2024.03.014","article-title":"Gut microbiome and metabolome profiling in Framingham heart study reveals cholesterol-metabolizing bacteria","volume":"187","author":"Li","year":"2024","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-022-00794-0","article-title":"The gut microbiota in obesity and weight management: microbes as friends or foe","volume":"19","author":"Van Hul","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.125140","article-title":"Microbiota-gut-kidney axis in health and renal disease","volume":"22","author":"Jin","year":"2026","journal-title":"Int J Biol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2024.1380713","article-title":"Intestinal barrier permeability: the influence of gut microbiota, nutrition, and exercise","volume":"15","author":"Dmytriv","year":"2024","journal-title":"Front Physiol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-023-03374-w","article-title":"Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review","volume":"19","author":"Di Vincenzo","year":"2024","journal-title":"Intern Emerg Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-023-03262-3","article-title":"Are gut dysbiosis, barrier disruption, and endotoxemia related to adipose tissue dysfunction in metabolic disorders? Overview of the mechanisms involved","volume":"18","author":"Rosendo-Silva","year":"2023","journal-title":"Intern Emerg Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00704.2025","article-title":"From gut to blood: barrier dysfunction as a driver of systemic low-grade inflammation in cardiometabolic disease","volume":"329","author":"Yang-Jensen","year":"2025","journal-title":"Am J Physiol Cell Physiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104670","article-title":"Altered gut microbiota of obesity subjects promotes colorectal carcinogenesis in mice","volume":"93","author":"Kang","year":"2023","journal-title":"EBioMedicine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13766","article-title":"Deciphering the complex interplay of obesity, epithelial barrier dysfunction, and tight junction remodeling: Unraveling potential therapeutic avenues","volume":"25","author":"AlMarzooqi","year":"2024","journal-title":"Obes Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2026.1842279","article-title":"Host\u2013microbiome interactions in leukemia: mechanisms, treatment response, and clinical implications","volume":"16","author":"Bautista","year":"2026","journal-title":"Front Cell Infect Microbiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594150","article-title":"Role of metabolic endotoxemia in systemic inflammation and potential interventions","volume":"11","author":"Mohammad","year":"2020","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.biochi.2015.06.020","article-title":"Metabolic endotoxemia with obesity: Is it real and is it relevant","volume":"124","author":"Boutagy","year":"2016","journal-title":"Biochimie"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s42003-024-07437-2","article-title":"Brd4 modulates metabolic endotoxemia-induced inflammation by regulating colonic macrophage infiltration in high-fat diet-fed mice","volume":"7","author":"Hu","year":"2024","journal-title":"Commun Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"15197","DOI":"10.1038\/s41598-023-42377-7","article-title":"Treatment with Ligilactobacillus murinus lowers blood pressure and intestinal permeability in spontaneously hypertensive rats","volume":"13","author":"Mukohda","year":"2023","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70159","article-title":"Gut dysbiosis as a shared mechanism in obesity and hypertension: exploring a promising therapeutic avenue","volume":"9","author":"Belan\u010di\u0107","year":"2026","journal-title":"Endocrinol Diabetes Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae499","article-title":"Exploring the gut microbiota: key insights into its role in obesity, metabolic syndrome, and type 2 diabetes","volume":"109","author":"Sasidharan Pillai","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1380476","article-title":"The potential of short-chain fatty acid epigenetic regulation in chronic low-grade inflammation and obesity","volume":"15","author":"Kopczy\u0144ska","year":"2024","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf9382","article-title":"Metaflammation in obesity and its therapeutic targeting","volume":"15","author":"Schleh","year":"2023","journal-title":"Sci Transl Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s44466-026-00040-6","article-title":"Toll-like receptors in innate immunity and inflammation: from fundamental biology to clinic insights","volume":"2","author":"Qian","year":"2026","journal-title":"Immun Inflammation"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1121695","article-title":"Mechanisms of gut microbiota-immune-host interaction on glucose regulation in type 2 diabetes","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Microbiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3390\/ijerph18020511","article-title":"Role of NLRP3 inflammasome activation in obesity-mediated metabolic disorders","volume":"18","author":"Wani","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2026.103399","article-title":"Reprogramming macrophage metabolism for cardiovascular therapy: From molecular pathways to precision nanomedicine","volume":"39","author":"Guo","year":"2026","journal-title":"Mater Today Bio"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.cmet.2022.08.003","article-title":"Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation","volume":"34","author":"Wong","year":"2022","journal-title":"Cell Metab"},{"key":"B48","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1038\/s41467-024-48935-5","article-title":"Obesity-associated microbiomes instigate visceral adipose tissue inflammation by recruitment of distinct neutrophils","volume":"15","author":"Shantaram","year":"2024","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3390\/ijms27031237","article-title":"Insulin resistance and inflammation","volume":"27","author":"Gusev","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.20752","article-title":"Sex differences in association between gut microbiome and essential hypertension based on ambulatory blood pressure monitoring","volume":"80","author":"Virwani","year":"2023","journal-title":"Hypertension"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.123.322055","article-title":"Gut microbiota and microbial metabolism in early risk of cardiometabolic disease","volume":"132","author":"Gabriel","year":"2023","journal-title":"Circ Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12986-025-01051-7","article-title":"Gut microbiota-cholesterol crosstalk in cardiovascular diseases: mechanisms, metabolites, and therapeutic modulation","volume":"23","author":"Abavisani","year":"2025","journal-title":"Nutr Metab (Lond)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1333778","article-title":"Gut microbiota and therapy for obesity and type 2 diabetes","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06198-1","article-title":"The gut microbiota and diabetes: research, translation, and clinical applications - 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum","volume":"67","author":"Byndloss","year":"2024","journal-title":"Diabetologia"},{"key":"B55","doi-asserted-by":"publisher","first-page":"002117","DOI":"10.1099\/jmm.0.002117","article-title":"SCFAs\u2019 pleiotropic role in pathogenesis and salutogenesis: mechanisms in exacerbation and regulation of inflammation and fibrosis from gut to host","volume":"75","author":"Ahmad","year":"2026","journal-title":"J Med Microbiol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2014.153","article-title":"The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents","volume":"39","author":"Psichas","year":"2015","journal-title":"Int J Obes (Lond)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.124.325770","article-title":"Gut microbiota metabolites sensed by host GPR41\/43 protect against hypertension","volume":"136","author":"R Muralitharan","year":"2025","journal-title":"Circ Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202501579RR","article-title":"Gut microbiota-derived metabolites orchestrate metabolic reprogramming in diabetic cardiomyopathy: mechanisms and therapeutic frontiers","volume":"39","author":"Jin","year":"2025","journal-title":"FASEB J"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1887873","article-title":"The microbiome as a systems-level regulator of immune, metabolic, neural, and endocrine signaling in cancer","volume":"17","author":"Bautista","year":"2026","journal-title":"Front Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s00253-024-13007-7","article-title":"Therapeutic applications of gut microbes in cardiometabolic diseases: current state and perspectives","volume":"108","author":"Yuan","year":"2024","journal-title":"Appl Microbiol Biotechnol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1085041","article-title":"The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases","volume":"14","author":"Zhen","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-025-05356-2","article-title":"The effect of TMAO on aging-associated cardiovascular and metabolic pathways and emerging therapies","volume":"480","author":"Alsulami","year":"2025","journal-title":"Mol Cell Biochem"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.4014\/jmb.2503.03045","article-title":"Indole propionic acid regulates gut immunity: mechanisms of metabolite-driven immunomodulation and barrier integrity","volume":"35","author":"Ren","year":"2025","journal-title":"J Microbiol Biotechnol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.114149","article-title":"Indole-3-propionic acid exacerbates cisplatin-induced chronic kidney disease through the AHR\/NF-\u03baB signaling pathway","volume":"28","author":"Wang","year":"2025","journal-title":"iScience"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2023.03.008","article-title":"Microbially produced imidazole propionate is associated with heart failure and mortality","volume":"11","author":"Molinaro","year":"2023","journal-title":"JACC Heart Fail"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09263-w","article-title":"Imidazole propionate is a driver and therapeutic target in atherosclerosis","volume":"645","author":"Mastrangelo","year":"2025","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","first-page":"6696","DOI":"10.1038\/s41467-024-50855-3","article-title":"Gut microbe-generated phenylacetylglutamine is an endogenous allosteric modulator of \u03b22-adrenergic receptors","volume":"15","author":"Saha","year":"2024","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2022.2111952","article-title":"Type 2 diabetes, gut microbiome, and systems biology: a novel perspective for a new era","volume":"14","author":"Mart\u00ednez-L\u00f3pez","year":"2022","journal-title":"Gut Microbes"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102571","article-title":"Gut microbiota and metabolic disease risk in youth","volume":"7","author":"Xie","year":"2026","journal-title":"Cell Rep Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042220-012821","article-title":"The gut microbiome: connecting diet, glucose homeostasis, and disease","volume":"73","author":"Howard","year":"2022","journal-title":"Annu Rev Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.3390\/biomedicines13092173","article-title":"The gut microbiome in human obesity: a comprehensive review","volume":"13","author":"Borrego-Ruiz","year":"2025","journal-title":"Biomedicines"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1186\/s12263-021-00703-6","article-title":"Gut microbiota in patients with obesity and metabolic disorders - a systematic review","volume":"17","author":"Xu","year":"2022","journal-title":"Genes Nutr"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1486793","article-title":"A systematic review on gut microbiota in type 2 diabetes mellitus","volume":"15","author":"Chong","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03067-7","article-title":"Strain-specific gut microbial signatures in type 2 diabetes identified in a cross-cohort analysis of 8,117 metagenomes","volume":"30","author":"Mei","year":"2024","journal-title":"Nat Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02260-4","article-title":"Cardiometabolic health, diet and the gut microbiome: a meta-omics perspective","volume":"29","author":"Valles-Colomer","year":"2023","journal-title":"Nat Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S477494","article-title":"Alterations in the gut microbiota composition in obesity with and without type 2 diabetes: a pilot study","volume":"17","author":"Wang","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.08.018","article-title":"Gut microbiota-derived indole-3-propionic acid alleviates diabetic kidney disease through its mitochondrial protective effect via reducing ubiquitination mediated-degradation of SIRT1","volume":"73","author":"Zeng","year":"2025","journal-title":"J Advanc Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1016\/j.cmet.2023.06.010","article-title":"Gut microbiota modulate distal symmetric polyneuropathy in patients with diabetes","volume":"35","author":"Yang","year":"2023","journal-title":"Cell Metab"},{"key":"B79","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4103\/jod.jod_143_24","article-title":"The impact of gut microbiota in the development and management of diabetes","volume":"16","author":"Krishna","year":"2025","journal-title":"J Diabetol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s43856-025-00980-x","article-title":"The association between the gut microbiome and 24-h blood pressure measurements in the SCAPIS study","volume":"5","author":"Lin","year":"2025","journal-title":"Commun Med (London)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.chom.2020.06.004","article-title":"Arrhythmic gut microbiome signatures predict risk of type 2 diabetes","volume":"28","author":"Reitmeier","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B82","doi-asserted-by":"publisher","first-page":"12","DOI":"10.17925\/HI.2025.19.2.3","article-title":"Gut microbiome and cardiovascular health: mechanisms, therapeutic potential and future directions","volume":"19","author":"Edpuganti","year":"2025","journal-title":"Heart Int"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2026.1801100","article-title":"The hallmarks of host-microbiome decoupling","volume":"17","author":"Bautista","year":"2026","journal-title":"Front Microbiol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101557","article-title":"Role of gut microbe-derived metabolites in cardiometabolic diseases: systems based approach","volume":"64","author":"Cao","year":"2022","journal-title":"Mol Metab"},{"key":"B85","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s43556-022-00091-2","article-title":"The role of the gut microbiota in health and cardiovascular diseases","volume":"3","author":"Wang","year":"2022","journal-title":"Mol BioMed"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-075180","article-title":"Evidence for clinical interventions targeting the gut microbiome in cardiometabolic disease","volume":"383","author":"Ghosh","year":"2023","journal-title":"BMJ"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1737582","article-title":"Decoding the microbial blueprint of pancreatic cancer","volume":"13","author":"Bautista","year":"2026","journal-title":"Front Med (Lausanne)"},{"key":"B88","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3390\/metabo12010065","article-title":"The interaction between the gut microbiome and bile acids in cardiometabolic diseases","volume":"5","author":"Callender","year":"2022","journal-title":"Metabolites"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2025.05.002","article-title":"The role of gut microbiota in cardiovascular diseases and their potential as novel therapeutic targets","volume":"86","author":"Yamashita","year":"2025","journal-title":"J Cardiol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/biomedicines12010160","article-title":"Altered expression of intestinal tight junction proteins in heart failure patients with reduced or preserved ejection fraction: a pathogenetic mechanism of intestinal hyperpermeability","volume":"12","author":"Koufou","year":"2024","journal-title":"Biomedicines"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.803744","article-title":"Gut microbiota in heart failure patients with preserved ejection fraction (GUMPTION study)","volume":"8","author":"Huang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.123.322381","article-title":"Indole-3-propionic acid protects against heart failure with preserved ejection fraction","volume":"134","author":"Wang","year":"2024","journal-title":"Circ Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1801912","article-title":"The gut-kidney axis in chronic kidney disease: a vicious cycle of microbial dysbiosis and uremic toxin accumulation","volume":"17","author":"Guan","year":"2026","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.4103\/tcmj.tcmj_293_24","article-title":"Gut-derived uremic toxins and cardiovascular health in chronic kidney disease","volume":"37","author":"Chen","year":"2025","journal-title":"Tzu Chi Med J"},{"key":"B95","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3390\/medicina62030444","article-title":"Heart-gut axis in cardiometabolic disease: microbiome-mediated pathways linking metabolic syndrome to cardiovascular risk","volume":"62","author":"Be\u010di\u0107","year":"2026","journal-title":"Med (Kaunas)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2024.103118","article-title":"The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: a systematic review, meta-analysis, and meta-regression of clinical trials","volume":"18","author":"Kaul","year":"2024","journal-title":"Diabetes Metab Syndr"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112678","article-title":"The links between gut microbiota and obesity and obesity related diseases","volume":"147","author":"Geng","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-022-00698-6","article-title":"Recent advances in modulation of cardiovascular diseases by the gut microbiota","volume":"36","author":"Masenga","year":"2022","journal-title":"J Hum Hypertens"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/obr.70037","article-title":"Impacts of lifestyle and microbiota-targeted interventions for overweight and obesity on the human gut microbiome: a systematic review","volume":"27","author":"Lee","year":"2026","journal-title":"Obes Rev"},{"key":"B100","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/antiox15060727","article-title":"Probiotic modulation of gut microbiota: antioxidant mechanisms and clinical benefits in obesity and type 2 diabetes management","volume":"15","author":"Barakat","year":"2026","journal-title":"Antioxidants (Basel)"},{"key":"B101","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.cmet.2024.12.010","article-title":"Akkermansia muciniphila supplementation in patients with overweight\/obese type 2 diabetes: Efficacy depends on its baseline levels in the gut","volume":"37","author":"Zhang","year":"2025","journal-title":"Cell Metab"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.3390\/biom12111640","article-title":"Postbiotics and their health modulatory biomolecules","volume":"12","author":"Scott","year":"2022","journal-title":"Biomolecules"},{"key":"B103","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12986-025-01037-5","article-title":"The effect of postbiotics supplementation on obesity and metabolic health: a systematic review and meta-analysis of randomized control trials","volume":"22","author":"Li","year":"2025","journal-title":"Nutr Metab (Lond)"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2345134","article-title":"Recipient microbiome-related features predicting metabolic improvement following fecal microbiota transplantation in adults with severe obesity and metabolic syndrome: a secondary analysis of a phase 2 clinical trial","volume":"16","author":"Zhang","year":"2024","journal-title":"Gut Microbes"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/j.clinthera.2023.11.015","article-title":"The effect of fecal microbiota transplantation on cardiometabolic risk factors: A systematic review and meta-analysis","volume":"46","author":"Pakmehr","year":"2024","journal-title":"Clin Ther"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2025.100419","article-title":"Probiotics, prebiotics, synbiotics, and FMT for glycemic control: A systematic review of clinical efficacy and mechanistic readouts in type 2 diabetes and related dysglycemia","volume":"28","author":"Shalbaf","year":"2025","journal-title":"Metab Open"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3390\/life14111485","article-title":"Impact of gut microbiome interventions on glucose and lipid metabolism in metabolic diseases: A systematic review and meta-analysis","volume":"14","author":"Mederle","year":"2024","journal-title":"Life (Basel)"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1096\/fj.14-265983","article-title":"Alteration of gut microbiota by vancomycin and bacitracin improves insulin resistance via glucagon-like peptide 1 in diet-induced obesity","volume":"29","author":"Hwang","year":"2015","journal-title":"FASEB J"},{"key":"B109","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cmet.2016.06.016","article-title":"Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: A randomized double-blind placebo-controlled trial","volume":"24","author":"Reijnders","year":"2016","journal-title":"Cell Metab"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110649","article-title":"Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults","volume":"39","author":"Anthony","year":"2022","journal-title":"Cell Rep"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-00148","article-title":"Effect of rifaximin treatment on endotoxemia and insulin sensitivity in humans","volume":"3","author":"Finlin","year":"2019","journal-title":"J Endocr Soc"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2604867","article-title":"Microbes and medicines: interrelationships between pharmaceuticals and the gut microbiome","volume":"18","author":"Al-Btoosh","year":"2026","journal-title":"Gut Microbes"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1149256","article-title":"Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment","volume":"14","author":"Jia","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4345","article-title":"Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug","volume":"23","author":"Wu","year":"2017","journal-title":"Nat Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0222-4","article-title":"Gut microbiota and intestinal FXR mediate the clinical benefits of metformin","volume":"24","author":"Sun","year":"2018","journal-title":"Nat Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2021.101223","article-title":"Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes","volume":"47","author":"Smits","year":"2021","journal-title":"Diabetes Metab"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.814770","article-title":"Gut microbial signatures for glycemic responses of GLP-1 receptor agonists in type 2 diabetic patients: A pilot study","volume":"12","author":"Tsai","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B118","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1038\/s41598-026-36318-3","article-title":"Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake","volume":"16","author":"Klemets","year":"2026","journal-title":"Sci Rep"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac210","article-title":"Cardiovascular benefits of empagliflozin are associated with gut microbiota and plasma metabolites in type 2 diabetes","volume":"107","author":"Deng","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B120","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1038\/s41598-020-62261-y","article-title":"Rosuvastatin alters the genetic composition of the human gut microbiome","volume":"10","author":"Kummen","year":"2020","journal-title":"Sci Rep"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02951-6","article-title":"Effects of a personalized nutrition program on cardiometabolic health: a randomized controlled trial","volume":"30","author":"Bermingham","year":"2024","journal-title":"Nat Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v18.i3.116780","article-title":"Gut microbiota-derived metabolite trimethylamine N-oxide in major adverse cardiovascular events: Mechanisms, risk assessment, and therapeutic strategies","volume":"18","author":"Jaimez Alvarado","year":"2026","journal-title":"World J Cardiol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2026.1776983","article-title":"Biohacking the human gut microbiome for precision health and therapeutic innovation","volume":"17","author":"Bautista","year":"2026","journal-title":"Front Microbiol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac004","article-title":"The metabolic role and therapeutic potential of the microbiome","volume":"43","author":"Olofsson","year":"2022","journal-title":"Endocr Rev"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.903570","article-title":"The gut microbiota (microbiome) in cardiovascular disease and its therapeutic regulation","volume":"12","author":"Rahman","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1114424","article-title":"Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus","volume":"14","author":"Wu","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fragi.2026.1794192","article-title":"The microbiome-gerogene axis: a new frontier in precision geromedicine","volume":"7","author":"Bautista","year":"2026","journal-title":"Front Aging"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03642-6","article-title":"Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes","volume":"31","author":"Wu","year":"2025","journal-title":"Nat Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-026-01525-9","article-title":"Gut microbiota responses to bariatric surgery are associated with metabolic outcomes and type 2 diabetes remission","volume":"8","author":"Olsson","year":"2026","journal-title":"Nat Metab"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering13020144","article-title":"Transformer models, graph networks, and generative AI in gut microbiome research: A narrative review","volume":"13","author":"Zhu","year":"2026","journal-title":"Bioengineering (Basel)"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2026.1857151","article-title":"Programming the tumor microenvironment through microbiome-driven mechanisms","volume":"16","author":"Bautista","year":"2026","journal-title":"Front Cell Infect Microbiol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1038\/s41467-026-69405-0","article-title":"A gut microbiome-kidney-heart axis predictive of future cardiovascular diseases","volume":"17","author":"Chechi","year":"2026","journal-title":"Nat Commun"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70066","article-title":"Pharmacomicrobiomics","volume":"118","author":"Gronich","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"B134","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s44395-026-00045-5","article-title":"Pharmacomicrobiomics mechanisms clinical applications and analytical approaches","volume":"2","author":"Neelam","year":"2026","journal-title":"Discov Pharm Sci"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2269-x","article-title":"Statin therapy is associated with lower prevalence of gut microbiota dysbiosis","volume":"581","author":"Vieira-Silva","year":"2020","journal-title":"Nature"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1948038\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:21:27Z","timestamp":1787664087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1948038\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":135,"alternative-id":["10.3389\/fendo.2026.1948038"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1948038","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1948038"}}